Radioactive bullet targets Hard-to-Treat breast cancer
Disease control
Recruiting now
This early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, toler…
Phase: PHASE1 • Sponsor: Affibody • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC